Precision Medicine in Oncology®

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Latest News

FDA
FDA Accepts NDA for Ensartinib in Metastatic ALK+ NSCLC

March 13th 2024

The FDA has accepted a new drug application for ensartinib in metastatic ALK-positive non–small cell lung cancer.

US FDA
TERN-701 Receives FDA Orphan Drug Designation in CML

March 12th 2024

Giuseppe Curigliano, MD, PhD
Targeted Delivery of IL-12 Shows Preliminary Antitumor Activity in Advanced Solid Tumors

March 11th 2024

stock.adobe.com
ABSK061 Demonstrates Safety, Preliminary Efficacy in FGFR2/3+ Advanced Solid Tumors

March 7th 2024

FDA
FDA Approval Highlights: OncLive’s February Recap

February 29th 2024

Video Series
Video Interviews
Podcasts

More News